GlassScriptPhysician profile
Ashley Lorrain Smith
NPI 1629425210
$627.92
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $131.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $123.79 | 2022 | |
| Abbvie INC. | $106.99 | 2021-2022 | |
| Vifor Pharma, INC. | $80.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.81 | 2021 | |
| Paratek Pharmaceuticals, INC. | $31.36 | 2021 | |
| Astellas Pharma US INC | $30.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.10 | 2022 | |
| Pfizer INC. | $20.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.79 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.